{
  "extraction_date": "2025-12-23",
  "condition": "AUTISM",
  "phase": "3",
  "priority": "Expansion",
  "total_studies": 3,
  "studies": [
    {
      "study_id": "CT_NCT03886753",
      "study_type": "Clinical Trial",
      "condition": "AUTISM",
      "study_title": "Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products",
      "citation": "ClinicalTrials.gov NCTNCT03886753",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in symptoms"
        ],
        "outcome_measures": [
          "Change in symptoms"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03886753",
        "enrollment": 10,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03886753"
      }
    },
    {
      "study_id": "CT_NCT03677089",
      "study_type": "RCT",
      "condition": "AUTISM",
      "study_title": "Extension for Community Healthcare Outcomes Autism Replication Evaluation",
      "citation": "ClinicalTrials.gov NCTNCT03677089",
      "publication_year": 2018,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Longitudinal Pattern of ASD Screening in PCP Charts",
          "Longitudinal Pattern of Reported Co-occurring Medical Conditions Correctly Treated in PCP Charts"
        ],
        "outcome_measures": [
          "Longitudinal Pattern of ASD Screening in PCP Charts",
          "Longitudinal Pattern of Reported Co-occurring Medical Conditions Correctly Treated in PCP Charts"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03677089",
        "enrollment": 148,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03677089"
      }
    },
    {
      "study_id": "CT_NCT05302167",
      "study_type": "RCT",
      "condition": "AUTISM",
      "study_title": "Molehill Mountain Feasibility Study.",
      "citation": "ClinicalTrials.gov NCTNCT05302167",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in 7-item Generalised Anxiety Disorder Scale (GAD-7)",
          "App acceptability/ feasibility survey"
        ],
        "outcome_measures": [
          "Change in 7-item Generalised Anxiety Disorder Scale (GAD-7)",
          "App acceptability/ feasibility survey"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05302167",
        "enrollment": 100,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05302167"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 3,
    "pubmed_added": 0,
    "total_added": 3,
    "expansion_date": "2025-12-23T23:42:20.378710"
  }
}